{"id":"NCT05514873","sponsor":"UCB Biopharma SRL","briefTitle":"An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors","officialTitle":"A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-10-31","primaryCompletion":"2024-03-13","completion":"2024-10-23","firstPosted":"2022-08-25","resultsPosted":"2025-03-30","lastUpdate":"2025-09-03"},"enrollment":26,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Myasthenia Gravis"],"interventions":[{"type":"DRUG","name":"zilucoplan (RA101495)","otherNames":[]}],"arms":[{"label":"0.3 mg/kg zilucoplan (RA101495)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period","timeFrame":"From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)","effectByArm":[{"arm":"Zilucoplan 0.3 mg/kg","deltaMin":73.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":18},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["40620733"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":26},"commonTop":["Amylase increased","Lipase increased","COVID-19","Diarrhoea","Nausea"]}}